MedTrace Logo

Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum

NCT06581796 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-11-27

No results posted yet for this study

Summary

In this study, the investigators planned to investigate maternal serum pepsinogen-1 (MSPG-1) levels in pregnant women with severe hyperemesis gravidarum (HG) and pregnant women without severe HG.

HG is the most common cause of hospitalization in the first trimester of pregnancy and represents an economic burden on the healthcare system. Therefore, our aim in this study was to investigate whether there is a statistical difference in MSPG-1 levels between pregnant women with severe HG and pregnant women without severe HG and to determine a cut-off value for MSPG-1 levels for the indication of hospitalization of pregnant women with HG.

The study poses no risk to the pregnant woman or the fetus.

Conditions

  • Hyperemesis Gravidarum
  • Pregnant With Complication

Interventions

OTHER

pepsinogen-1

association between pepsinogen 1 serum level with hyperemesis gravidarum

Sponsors & Collaborators

  • Ankara Etlik City Hospital

    lead OTHER_GOV

Principal Investigators

  • Sevki Celen, MD · Ankara Etlik City Hospital

Eligibility

Min Age
21 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-09-10
Completion
2024-11-21

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06581796 on ClinicalTrials.gov